News

The lowest dose of cannabinor, a CB2 agonist, produced a statistically significant decrease in pain versus placebo, as measured by the primary endpoint. However, this drug effect was

<p>Fiege said it marks the beginning of a comprehensive logistical co-operation within the healthcare segment in the Netherlands between Fiege and Twente Group of Hospitals, i.e. Ziekenhuisgroep Twente.

If approved, maraviroc would be the first member of a new class of oral HIV medicines in more than a decade. Maraviroc is a CCR5 antagonist, for use

The approvable letter indicated that before the new drug application can be cleared the FDA must receive and analyze final safety and efficacy data from the recently completed

The agreement also includes potential payments of up to $55 million based on meeting certain profit targets and product development targets for Alliant’s products. The company expects to

Under the terms of the agreement, US-based biopharmaceutical company VGX will have exclusive worldwide rights to develop a number of DNA plasmids and constructs with potential for the

The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate and 54 patients receiving treatment with mid-strength steroid

The company conducted two phase III double-blind, placebo-controlled studies in which Huntingdon's patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of miraxion

Lexicon said that LX1031 was found to be well-tolerated at all doses tested in the recently completed phase Ia trial. “The safety and pharmacokinetic profile exhibited by LX1031